GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (OTCPK:TCON) » Definitions » 3-Year RORE %

TCON (TRACON Pharmaceuticals) 3-Year RORE % : -4.93% (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. TRACON Pharmaceuticals's 3-Year RORE % for the quarter that ended in Jun. 2024 was -4.93%.

The industry rank for TRACON Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

TCON's 3-Year RORE % is not ranked
in the Biotechnology industry.
Industry Median: -9.955 vs TCON: -4.93

TRACON Pharmaceuticals 3-Year RORE % Historical Data

The historical data trend for TRACON Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TRACON Pharmaceuticals 3-Year RORE % Chart

TRACON Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.00 -49.08 -51.33 -14.12 50.91

TRACON Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.03 53.89 50.91 -5.80 -4.93

Competitive Comparison of TRACON Pharmaceuticals's 3-Year RORE %

For the Biotechnology subindustry, TRACON Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TRACON Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's 3-Year RORE % falls into.



TRACON Pharmaceuticals 3-Year RORE % Calculation

TRACON Pharmaceuticals's 3-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -21.34--31.4 )/( -204.08-0 )
=10.06/-204.08
=-4.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 3-year before.


TRACON Pharmaceuticals  (OTCPK:TCON) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


TRACON Pharmaceuticals 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


TRACON Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer director, officer: President and CEO C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams officer: Chief Operating Officer C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown officer: Chief Accounting Officer (PAO) C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue director C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins officer: Chief Business Officer 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani 10 percent owner, other: Member of 10% Group 12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc 10 percent owner 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022